Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/7/2005


1.		Phase II Study of Monoclonal Antibody 3F8 with Sargramostim (GM-CSF) in Patients with Advanced Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				2 to 21				Other				MSKCC-94018 NCI-V94-0416, NCT00002560

Last Modified: 12/6/2007


2.		Phase II Study of Intensive Multimodality Therapy for Poor Risk Neuroblastoma: Sequential Cyclophosphamide, Doxorubicin, and Vincristine Along With Cisplatin and Etoposide, External-Beam Radiotherapy, and Radioimmunotherapy With Iodoine I 131 Monoclonal Antibody (MOAB 3F8) Followed by Autologous Bone Marrow Transplantation and Immunotherapy With MOAB 3F8

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 1 at diagnosis				Other				MSKCC-94011A1 MSKCC-FDR001041, NCI-V95-0622, NCT00002634

Last Modified: 10/3/2003 First Published: 11/1/1999


3.		Phase II Study of Monoclonal Antibody 3F8, Etoposide, and Isotretinoin in Patients With High-Risk Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Not specified				NCI				MSKCC-IRB-99033 NCI-G99-1599, NCT00004110

Last Modified: 4/7/2005 First Published: 7/1/2002


4.		Phase II Study of Multimodality Therapy Comprising Dose-Intensive Induction Chemotherapy, Monoclonal Antibody 3F8, Surgery, Myeloablative Chemotherapy, Autologous or Syngeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation, Radiotherapy, and Isotretinoin in Patients With Advanced Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				50 and under				NCI				MSKCC-00065 NCI-G02-2083, NCT00040872

Last Modified: 8/1/1991


5.		Phase II Study of Antiganglioside GD2-Specific Mouse MOAB 3F8 in Patients with Neuroblastoma in Early Relapse (Summary Last Modified 08/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				under 18								MSKCC-87059 NCI-V88-0353

Last Modified: 4/1/2000


6.		Phase II Study of Adjuvant Therapy with Antiganglioside GD2-Specific Mouse Monoclonal Antibody 3F8 for Metastatic Neuroblastoma in Second Remission

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				under 18				Other				MSKCC-87118 NCI-V88-0357, NCT00002458

Last Modified: 1/1/1991


7.		Phase II Study of the N6 Regimen Involving Intensive Chemotherapy with CAV (CTX/DOX/VCR) and PVP (VP-16/CDDP) with Adjuvant MOAB 3F8, plus Surgery and Radiotherapy as Appropriate, in Patients with Poor-Risk Neuroblastoma (Summary Last Modified 01/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				any age								MSKCC-89175A2 NCI-V90-0023

Last Modified: 7/19/2007 First Published: 7/23/2004


8.		Phase II Study of Monoclonal Antibody 3F8, Beta-Glucan, Isotretinoin and Sargramostim (GM-CSF) in Patients With High-Risk Refractory Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Any age				NCI				MSKCC-04050 NCT00089258

Last Modified: 11/5/2004 First Published: 5/1/2002


9.		Phase I Study of beta-Glucan and Monoclonal Antibody 3F8 in Patients With Metastatic Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				Under 50				NCI				MSKCC-01075 NCI-G02-2067, NCT00037011

Last Modified: 8/1/1988


10.		Phase I Study of Anti-GD2 (3F8) and Anti-GD3 (R24) Mouse Monoclonal Antibodies in Patients with Metastatic Melanoma or Soft Tissue Sarcoma (Summary Last Modified 08/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over								MSKCC-86066 NCI-V88-0387

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute